Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dapsone-induced peripheral neuropathy.

E M Ahrens, R J Meckler, J P Callen

    International Journal of Dermatology
    |June 1, 1986
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Anti-C1q antibodies in systemic lupus erythematosus.

    Lupus·2014
    Same author

    Hypertrophic lupus erythematosus complicating long-standing systemic lupus erythematosus.

    Lupus·2011
    Same author

    Drug-induced subacute cutaneous lupus erythematosus.

    Lupus·2010
    Same author

    Dermatology position paper on the revision of the 1982 ACR criteria for systemic lupus erythematosus.

    Lupus·2004
    Same author

    Vancomycin-induced linear IgA bullous disease presenting as toxic epidermal necrolysis.

    Clinical and experimental dermatology·2004
    Same author

    Update on the management of cutaneous lupus erythematosus.

    The British journal of dermatology·2004
    Same journal

    Updated Vitiligo Trends in the Burden of Psychiatric and Autoimmune Diseases.

    International journal of dermatology·2026
    Same journal

    SENTINOLD and the Challenge of Meaningful Risk Prediction in Melanoma.

    International journal of dermatology·2026
    Same journal

    The "Stamp-n-Tack" Technique: An Ink-Guided Precision Method for Anchoring Tissue After Releasing Facial Retaining Ligaments in Large Facial Flap Reconstruction.

    International journal of dermatology·2026
    Same journal

    Counterfactual Dermatology With Generative Models.

    International journal of dermatology·2026
    Same journal

    Correlation of Clinical and Histopathological Features With Anti-Desmoglein Antibody Profile in Pemphigus Patients.

    International journal of dermatology·2026
    Same journal

    Paracetamol-Induced Generalized Bullous Fixed Drug Eruption With Positive Anti-BP230 Antibody and Confirmed With Oral Provocation Test in a Child: A Case Report From the Philippines.

    International journal of dermatology·2026
    See all related articles

    Dapsone therapy for dermatitis herpetiformis can cause peripheral neuropathy. Stopping dapsone improved neurologic symptoms and nerve conduction, with sulfapyridine showing no adverse effects.

    Area of Science:

    • Neurology
    • Dermatology
    • Toxicology

    Background:

    • Dapsone is a common treatment for dermatitis herpetiformis.
    • Long-term dapsone use can lead to various side effects.
    • Peripheral neuropathy is a potential adverse effect of dapsone.

    Observation:

    • A young man with dermatitis herpetiformis experienced fatigue and neurologic symptoms after 4 years of dapsone treatment.
    • Clinical examination and nerve conduction studies indicated a combined motor and sensory peripheral neuropathy.
    • The patient's symptoms improved after discontinuing dapsone therapy.

    Findings:

    • Cessation of dapsone therapy led to symptomatic improvement in the patient's neuropathy.
    • Nerve conduction studies corroborated the clinical improvement.

    Related Experiment Videos

  • Switching to sulfapyridine did not impede the resolution of the neuropathy.

    • Implications:

    • This case highlights the risk of dapsone-induced peripheral neuropathy in dermatitis herpetiformis patients.
    • Early recognition and discontinuation of dapsone may reverse neurologic deficits.
    • Sulfapyridine can be a viable alternative for patients developing neuropathy on dapsone.